Clinical Research Directory
Browse clinical research sites, groups, and studies.
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Sponsor: VA Office of Research and Development
Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Official title: CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2540
Start Date
2024-05-22
Completion Date
2028-12-31
Last Updated
2026-01-09
Healthy Volunteers
No
Interventions
Metoprolol Succinate
a dialyzable, beta-1 selective beta blocker
Carvedilol
a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
Locations (8)
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California, United States
North Florida/South Georgia Veterans Health System, Gainesville, FL
Gainesville, Florida, United States
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia, United States
Iowa City VA Health Care System, Iowa City, IA
Iowa City, Iowa, United States
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts, United States
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, United States
New Mexico VA Health Care System, Albuquerque, NM
Albuquerque, New Mexico, United States